Tools
Sorted by:
Try your query at:
 |
 |
 |
 |
 |
 |
Results 1 - 10
of
683
Relative absorptive capacity and interorganizational learning
- STRATEGIC MANAGEMENT JOURNAL
, 1998
"... Much of the prior research on interorganizational learning has focused on the role of absorptive capacity, a firm’s ability to value, assimilate, and utilize new external knowledge. However, this definition of the construct suggests that a firm has an equal capacity to learn from all other organizat ..."
Abstract
-
Cited by 463 (2 self)
- Add to MetaCart
policies, and (3) dominant logics. We then test the model using a sample of pharmaceutical–biotechnology R&D alliances. As predicted, the similarity of the partners ’ basic knowledge, lower management formalization, research centrali-zation, compensation practices, and research communities were
Vertical alliance networks: The case of university–biotechnology–pharmaceutical alliance chains
, 2007
"... Many young biotechnology firms act as intermediaries in tripartite alliance chains. They enter upstream partnerships with public sector research institutions, and later form commercialization alliances with established, downstream firms. We examine the alliance activity in a large sample of biotechn ..."
Abstract
- Add to MetaCart
Many young biotechnology firms act as intermediaries in tripartite alliance chains. They enter upstream partnerships with public sector research institutions, and later form commercialization alliances with established, downstream firms. We examine the alliance activity in a large sample
Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
- Journal of Health Economics
, 2005
"... Using data on over 900 firms for the period 1988–2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm’s overall experience, its experience in the ..."
Abstract
-
Cited by 37 (0 self)
- Add to MetaCart
Using data on over 900 firms for the period 1988–2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm’s overall experience, its experience in the
Exploration and exploitation alliances in biotechnology: A system of new product development
- Strategic Management Journal
, 2004
"... We link the exploration–exploitation framework of organizational learning to a technology venture’s strategic alliances and argue that the causal relationship between the venture’s alliances and its new product development depends on the type of the alliance. In particular, we propose a product deve ..."
Abstract
-
Cited by 162 (5 self)
- Add to MetaCart
by firm size. As a technology venture grows, it tends to withdraw from this product development path to discover, develop, and commercialize promising projects through vertical integration. We test our model on a sample of 325 biotechnology firms that entered 2565 alliances over a 25-year period. We find
Contractibility and contract design in strategic alliances
- American Economic Review
"... Abstract The widespread use of strategic alliances between pharmaceutical and biotechnology companies is puzzling, since it is hard to contract on the exact nature of the research activities. A major concern of pharmaceutical companies entering strategic alliances is that the biotechnology firm wil ..."
Abstract
-
Cited by 5 (0 self)
- Add to MetaCart
Abstract The widespread use of strategic alliances between pharmaceutical and biotechnology companies is puzzling, since it is hard to contract on the exact nature of the research activities. A major concern of pharmaceutical companies entering strategic alliances is that the biotechnology firm
The Biotechnology Industry
"... Growth and change are the hallmarks of the developing biotechnology industry. Since the first approval of a biological product in 1982, over 40 biologicals, many of them medical breakthroughs, have been brought to market. The majority of biotechnology companies focus on developing human therapeutic ..."
Abstract
- Add to MetaCart
-quently used to enhance research capabilities. As the industry has matured, consolidation has occurred, with major pharmaceutical companies purchasing biotechnology companies and biotechnology com-panies merging to expand their capabilities. Research investment, as a percentage of gross sales, con
1 VALUING STRATEGIC ALLIANCES IN THE PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY SELECTED PAPER PREPARED FOR THE AAEA 2005 ANNUAL MEETINGS
"... copies of this document for non-commercial purposes by any means, provided that this copyright notice appears on such copies. 1 Correspondence to this author. ..."
Abstract
- Add to MetaCart
copies of this document for non-commercial purposes by any means, provided that this copyright notice appears on such copies. 1 Correspondence to this author.
Evidence from Biotechnology Alliances
"... anonymous referee, a number of practitioners, and participants in formal seminars and informal workshops at the American Law and Economics Association annual meetings, ..."
Abstract
- Add to MetaCart
anonymous referee, a number of practitioners, and participants in formal seminars and informal workshops at the American Law and Economics Association annual meetings,
THE CASE OF PHARMACEUTICAL BIOTECHNOLOGY
, 2004
"... Co-evolution in innovation systems: the case of pharmaceutical biotechnology ..."
Abstract
- Add to MetaCart
Co-evolution in innovation systems: the case of pharmaceutical biotechnology
Results 1 - 10
of
683
